Chelsea Bouvier
About Chelsea Bouvier
Chelsea Bouvier serves as the Director of Commercial Enablement at Sanguine, where she has significantly contributed to the company's growth and recognition in the research community. Her previous roles at Sanguine include Senior Account Executive and Sales Manager, and she has a background in communications and sales from various organizations.
Current Role at Sanguine
Chelsea Bouvier currently serves as the Director of Commercial Enablement at Sanguine, a position she has held since 2024. In this role, she focuses on enhancing the company's commercial strategies and operations. Prior to this, she worked as a Sales Manager at Sanguine from 2022 to 2024, where she contributed to the company's growth and success in the market.
Professional Experience at Sanguine
Chelsea Bouvier has a significant history with Sanguine, having joined the company in 2019 as an Account Executive. She progressed to the role of Senior Account Executive from 2020 to 2022. Throughout her tenure, she played a key role in expanding Sanguine's donor community, which now includes over 60,000 research-ready participants and more than 100 diverse patient advocacy groups.
Previous Employment History
Before her time at Sanguine, Chelsea worked at Oracle as a Core Technology Account Executive from 2017 to 2019 and as an HCM & ERP Cloud Applications Sales Representative from 2016 to 2017. She also held positions at W.B. Mason Company Inc. as a Sales Representative and Sales Trainer from 2012 to 2016, and she gained experience as an Assignment Desk Intern at WCVB-TV in 2011.
Education and Academic Background
Chelsea Bouvier earned her Bachelor's Degree in Communication and Media Studies from Stonehill College, where she studied from 2008 to 2012. Her education has provided her with a strong foundation in communication, which she has applied throughout her professional career.
Contributions and Achievements
Chelsea has contributed to Sanguine's recognition as a 'Great Place to Work' for the past three years. She has also been part of a team whose studies have been referenced in over 140 publications in high-impact journals, including Science, Nature, and NEJM. Additionally, she played a role in the development of disease-state leukapheresis products, specimen processing, and analytical laboratory services at Sanguine.